LuxCath, LLC is developing a real-time lesion visualization monitoring tool for use during cardiac ablation procedures. The LuxCath technology is based on breakthroughs discovered by cardiologist Dr. Marco Mercader and colleagues at George Washington University.

Atrial Fibrillation (AF) is a commonly occurring cardiac arrhythmia or irregular heartbeat characterized by lower quality of life, higher morbidity and mortality; and is a common cause of stroke, affecting approximately 2.5 million people in the U.S. alone. AF catheter ablation – an invasive procedure used to “disconnect” electrical pathway and restore normal heartbeat – is one of the fastest growing catheter-based cardiac procedures today. Radio Frequency Catheter Ablation (RFCA) is capable of blocking AF, however, to do so effectively and safely, a real-time damage monitoring tool is necessary. LuxCath is developing a catheter based real-time visualization monitoring tool for use during cardiac ablation procedures to ensure electrophysiologists are treating the right parts of the heart in atrial fibrillation patients effectively. This device could radically improve the speed of procedures and outcomes.


Contact Us

For more information please contact Omar Amirana, MD.


See All

LuxCath LLC, Awarded U.S. Patent for Real-time Lesion Visualization Technology Focused on Atrial Fib

• Groundbreaking innovation has immediate market application in the catheter treatment of Atrial Fibrillation (AF), the most common irregular heartbeat affliction. ..


Allied Minds and The George Washington University Partner to Form LuxCath LLC

Real-time visualization technology, based on collaborative research by Drs. Marco Mercader, M.D., a cardiologist; Matthew Kay, D.Sc., a biomedical engineer; and Narine Sar..

Please visit LuxCath at

Contact LuxCath

  • • Required
  • Captcha Image
  • Phone Email

Privacy Policy Terms of Use